^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | trastuzumab vedotin (MRG002) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer
Excerpt:
...- Must have histologically or cytologically confirmed HER2-positive metastatic, unresectable cancer and must have had prior disease progression on all standard therapies for their tumor....
Trial ID:
Source:
Title:
271P - First-in-human, phase I dose escalation and expansion study of anti-HER2 ADC MRG002 in patients with HER2 positive solid tumors
Published date:
09/13/2021
Excerpt:
In phase Ia dose escalation utilizing a “3+3” design, a total of 25 pts with BC (19), SGC (3), GC (2), and CRC (1) were enrolled to identify MTD/RP2D….The starting dose of MRG002 was 0.3 mg/kg, followed by 0.6, 1.2, 1.8, 2.2, 2.6, and 3.0 mg/kg, all pts with BC and GC had HER2+ per CAP guidelines....The dose escalation of MRG002 showed manageable safety profile and encouraging antitumor activity in pts with HER2+ solid tumors including BC, GC...
